Compass Therapeutics (CMPX)
Market Price (5/8/2026): $1.78 | Market Cap: $331.8 MilSector: Health Care | Industry: Biotechnology
Compass Therapeutics (CMPX)
Market Price (5/8/2026): $1.78Market Cap: $331.8 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -53% Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Biopharmaceutical R&D, Targeted Therapies, Show more. | Weak multi-year price returns2Y Excs Rtn is -28%, 3Y Excs Rtn is -117% Meaningful short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 14% | Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -75 Mil Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is null Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -24% Key risksCMPX key risks include [1] the historically low success rate for its class of novel anti-angiogenic therapies and [2] a dependency on future financing due to its history of significant losses and lack of approved products. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -53% |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Biopharmaceutical R&D, Targeted Therapies, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -28%, 3Y Excs Rtn is -117% |
| Meaningful short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 14% |
| Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -75 Mil |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is null |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -24% |
| Key risksCMPX key risks include [1] the historically low success rate for its class of novel anti-angiogenic therapies and [2] a dependency on future financing due to its history of significant losses and lack of approved products. |
Qualitative Assessment
AI Analysis | Feedback
Compass Therapeutics (CMPX) stock has lost about 70% since 1/31/2026 because of the following key factors:
1. Failure to meet the Overall Survival (OS) endpoint in the COMPANION-002 Phase 2/3 trial.
Compass Therapeutics announced on April 27, 2026, that its lead drug, tovecimig (CTX-009) combined with paclitaxel, did not meet the overall survival secondary endpoint in the COMPANION-002 study for second-line biliary tract cancer. The median overall survival was observed to be slightly worse than in the control arm.
2. Crossover of control patients complicated the interpretation of overall survival data.
Despite achieving a statistically significant improvement in the key secondary endpoint of progression-free survival (PFS) with a median of 4.7 months versus 2.6 months for the control arm (representing a 56% reduction in the risk of progression), the overall survival results were confounded. This was due to 54% of patients in the control arm crossing over to receive tovecimig after their disease progressed, making the overall survival data difficult to interpret and raising concerns about regulatory approval.
Show more
1. Failure to meet the Overall Survival (OS) endpoint in the COMPANION-002 Phase 2/3 trial.
Compass Therapeutics announced on April 27, 2026, that its lead drug, tovecimig (CTX-009) combined with paclitaxel, did not meet the overall survival secondary endpoint in the COMPANION-002 study for second-line biliary tract cancer. The median overall survival was observed to be slightly worse than in the control arm.
2. Crossover of control patients complicated the interpretation of overall survival data.
Despite achieving a statistically significant improvement in the key secondary endpoint of progression-free survival (PFS) with a median of 4.7 months versus 2.6 months for the control arm (representing a 56% reduction in the risk of progression), the overall survival results were confounded. This was due to 54% of patients in the control arm crossing over to receive tovecimig after their disease progressed, making the overall survival data difficult to interpret and raising concerns about regulatory approval.
Show more
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →
Stock Movement Drivers
Fundamental Drivers
The -71.7% change in CMPX stock from 1/31/2026 to 5/7/2026 was primarily driven by a -9.5% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 1312026 | 5072026 | Change |
|---|---|---|---|
| Stock Price ($) | 6.40 | 1.81 | -71.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 169 | 186 | -9.5% |
| Cumulative Contribution | 0.0% |
Market Drivers
1/31/2026 to 5/7/2026| Return | Correlation | |
|---|---|---|
| CMPX | -71.7% | |
| Market (SPY) | 3.6% | 15.7% |
| Sector (XLV) | -6.1% | 15.5% |
Fundamental Drivers
The -51.6% change in CMPX stock from 10/31/2025 to 5/7/2026 was primarily driven by a -25.8% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 10312025 | 5072026 | Change |
|---|---|---|---|
| Stock Price ($) | 3.74 | 1.81 | -51.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 138 | 186 | -25.8% |
| Cumulative Contribution | 0.0% |
Market Drivers
10/31/2025 to 5/7/2026| Return | Correlation | |
|---|---|---|
| CMPX | -51.6% | |
| Market (SPY) | 5.5% | 15.2% |
| Sector (XLV) | 1.2% | 20.1% |
Fundamental Drivers
The -2.7% change in CMPX stock from 4/30/2025 to 5/7/2026 was primarily driven by a null change in the company's Total Revenues ($ Mil).| (LTM values as of) | 4302025 | 5072026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.86 | 1.81 | -2.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1 | 0 | |
| P/S Multiple | 301.4 | ∞ | 9.2233720368547763E17% |
| Shares Outstanding (Mil) | 138 | 186 | -26.1% |
| Cumulative Contribution | 0.0% |
Market Drivers
4/30/2025 to 5/7/2026| Return | Correlation | |
|---|---|---|
| CMPX | -2.7% | |
| Market (SPY) | 30.4% | 16.9% |
| Sector (XLV) | 4.9% | 18.0% |
Fundamental Drivers
The -39.9% change in CMPX stock from 4/30/2023 to 5/7/2026 was primarily driven by a -36.7% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 4302023 | 5072026 | Change |
|---|---|---|---|
| Stock Price ($) | 3.01 | 1.81 | -39.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 118 | 186 | -36.7% |
| Cumulative Contribution | 0.0% |
Market Drivers
4/30/2023 to 5/7/2026| Return | Correlation | |
|---|---|---|
| CMPX | -39.9% | |
| Market (SPY) | 78.7% | 25.6% |
| Sector (XLV) | 13.9% | 23.5% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| CMPX Return | -20% | 59% | -69% | -7% | 270% | -65% | -53% |
| Peers Return | -14% | -22% | 18% | -9% | 7% | 14% | -11% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 8% | 96% |
Monthly Win Rates [3] | |||||||
| CMPX Win Rate | 0% | 58% | 8% | 42% | 67% | 40% | |
| Peers Win Rate | 40% | 47% | 50% | 53% | 47% | 56% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 60% | |
Max Drawdowns [4] | |||||||
| CMPX Max Drawdown | -28% | -61% | -72% | -49% | -3% | -69% | |
| Peers Max Drawdown | -29% | -45% | -23% | -29% | -41% | -12% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -7% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: XNCR, REGN, AMGN, MGNX, ZYME.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 5/7/2026 (YTD)
How Low Can It Go
| Event | CMPX | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -56.8% | -18.8% |
| % Gain to Breakeven | 131.5% | 23.1% |
| Time to Breakeven | 146 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -44.4% | -9.5% |
| % Gain to Breakeven | 80.0% | 10.5% |
| Time to Breakeven | 431 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -30.5% | -6.7% |
| % Gain to Breakeven | 43.9% | 7.1% |
| Time to Breakeven | 657 days | 31 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -64.3% | -24.5% |
| % Gain to Breakeven | 180.0% | 32.4% |
| Time to Breakeven | 219 days | 427 days |
In The Past
Compass Therapeutics's stock fell -56.8% during the 2025 US Tariff Shock. Such a loss loss requires a 131.5% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | CMPX | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -56.8% | -18.8% |
| % Gain to Breakeven | 131.5% | 23.1% |
| Time to Breakeven | 146 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -44.4% | -9.5% |
| % Gain to Breakeven | 80.0% | 10.5% |
| Time to Breakeven | 431 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -30.5% | -6.7% |
| % Gain to Breakeven | 43.9% | 7.1% |
| Time to Breakeven | 657 days | 31 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -64.3% | -24.5% |
| % Gain to Breakeven | 180.0% | 32.4% |
| Time to Breakeven | 219 days | 427 days |
In The Past
Compass Therapeutics's stock fell -56.8% during the 2025 US Tariff Shock. Such a loss loss requires a 131.5% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Compass Therapeutics (CMPX)
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops proprietary antibody-based therapeutics to treat multiple human diseases. The company's product candidates include CTX-009, an investigational bispecific antibody, which is in Phase II clinical trial for biliary tract cancers, as well as Phase Ib clinical trial for colorectal and ovarian cancer; CTX-471, a monoclonal antibody product candidate that is in Phase I clinical trial for patients with solid tumors, such as small cell lung cancer and melanoma; and CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 for oncology area. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
AI Analysis | Feedback
Here are 1-3 brief analogies for Compass Therapeutics (CMPX):
- A clinical-stage Amgen, but focused solely on cancer antibodies.
- A nascent Genentech, pioneering antibody drugs for cancer.
- The early-stage cancer therapeutics division of a future Bristol Myers Squibb.
AI Analysis | Feedback
```html- CTX-009: An investigational bispecific antibody in clinical trials for biliary tract, colorectal, and ovarian cancers.
- CTX-471: A monoclonal antibody product candidate undergoing Phase I clinical trial for various solid tumors, including small cell lung cancer and melanoma.
- CTX-8371: A bispecific inhibitor designed to target PD-1 and PD-L1 within the oncology area.
AI Analysis | Feedback
nullAI Analysis | Feedback
null
AI Analysis | Feedback
Thomas J. Schuetz, MD, PhD Chief Executive Officer
Thomas J. Schuetz co-founded Compass Therapeutics in 2014. He has over 20 years of experience in oncology, biopharmaceutical drug development, and life science venture investing. Prior to Compass, he was a venture partner at OrbiMed, where he co-founded Audentes Therapeutics, which was later acquired by Astellas. While at OrbiMed, he was involved in investments in and served as a director for Enobia Pharma (sold to Alexion), Relypsa (sold to Galenica), and Arteaus Therapeutics (sold to Eli Lilly). His previous roles also include chief medical officer of Therion Biologics Corporation and vice president of clinical affairs at Transkaryotic Therapies, a company acquired by Shire.
Barry Shin, JD, MBA Chief Financial Officer
Barry Shin was appointed Chief Financial Officer effective December 9, 2024. He brings over two decades of experience in the biopharmaceutical sector, having served as a public company executive, investment banker, and corporate attorney. Most recently, he was Executive Vice President, Chief Operating Officer & Chief Financial Officer at Trevena, Inc. Previously, Mr. Shin was a Managing Director in the Healthcare Investment Banking Groups at Mizuho Securities and Guggenheim Securities, and also held a position at Piper Sandler.
Arjun Prasad, MBA, MPH Chief Commercial Officer
Arjun Prasad was appointed Chief Commercial Officer effective January 1, 2026. He has over 15 years of commercial experience in biotech and large pharma. Before joining Compass, Mr. Prasad served as Chief Commercial Officer at Servier Pharmaceuticals. His experience also includes leadership roles at Agios Pharmaceuticals and Genentech, and he has been involved in over 10 oncology product launches.
Cynthia Sirard, MD Chief Medical Officer
Cynthia Sirard was appointed Chief Medical Officer effective January 1, 2026. Prior to Compass, she was Chief Medical Officer at Leap Therapeutics. Dr. Sirard also has clinical development leadership experience from her time at Sanofi and Genzyme. She is a gastrointestinal-focused medical oncologist who trained at Harvard Medical School's Beth Israel Deaconess Medical Center.
AI Analysis | Feedback
The key risks to Compass Therapeutics (CMPX), a clinical-stage oncology-focused biopharmaceutical company, are primarily centered around the success of its drug development pipeline, financial sustainability, and market competition.
- Clinical Trial Failure and Regulatory Approval: As a clinical-stage company, Compass Therapeutics' viability is heavily dependent on the successful completion of its clinical trials and obtaining regulatory approvals for its product candidates. The drug development process is lengthy, expensive, and inherently unpredictable, with a high rate of failure at various stages. For instance, historically, only a small percentage of developmental candidates successfully progress through Phase 2 and Phase 3 trials. The company's lead product candidate, CTX-009, is in Phase II/III trials, and the story could change quickly if these key trials disappoint. Furthermore, even if trials are successful, the regulatory approval processes by authorities like the FDA are time-consuming and uncertain, and failure to obtain approval would materially harm the business.
- Funding and Cash Burn: Compass Therapeutics consistently incurs significant net losses due to substantial research and development expenditures. For example, the company reported a net loss of US$66.49 million in 2025. This necessitates a continued reliance on external financing, often through equity offerings, which can lead to dilution for existing shareholders. While the company had approximately $209 million in cash and marketable securities as of December 31, 2025, expected to fund operations into 2028, the ongoing cash burn and the need to secure additional funding to advance its pipeline remain a central risk.
- Competition: The biotechnology and pharmaceutical industries are highly competitive. Compass Therapeutics faces significant competition from other companies developing similar antibody-based therapeutics and oncology treatments. The ability to compete effectively against established and emerging players is crucial for the company's operating results and the market acceptance of any approved products.
AI Analysis | Feedback
nullAI Analysis | Feedback
Compass Therapeutics, Inc. develops antibody-based therapeutics for various human diseases, primarily focusing on oncology. The addressable markets for its main products are detailed below:
CTX-009
- Biliary Tract Cancers: The global biliary tract cancer market size is projected to reach approximately $1.01 billion by 2030. Another estimate indicates the global market size is expected to grow from USD 0.675 billion in 2024 to USD 1.067 billion by 2035. The total market size for biliary tract cancer in the 7 Major Markets (7MM: United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan) was approximately USD 1.16 billion in 2024. In the United States alone, the market was approximately USD 700 million in 2024.
- Colorectal Cancer: The global colorectal cancer market size was valued at approximately $13 billion in 2023 and is anticipated to reach $20 billion by the end of 2032. Another report estimates the global market to be valued at USD 13.74 billion in 2025 and reach USD 19.08 billion by 2032. The total colorectal cancer market size across the 7MM was approximately USD 13,000 million in 2023. North America held a significant share, accounting for about 64.3% of the global market size in 2023.
- Ovarian Cancer: The global ovarian cancer drugs market generated USD 3,611.0 million in revenue in 2023 and is expected to reach USD 5,654.6 million by 2030. Another source reported the global ovarian cancer market size to be USD 3.5 billion in 2023, with a projection to reach approximately USD 6.5 billion by 2032. The ovarian cancer market size in the 7MM is expected to grow from USD 3,012 million in 2025 to USD 5,703 million in 2034. North America was the largest revenue-generating market in 2023, accounting for over 40% of the global market share. The US alone accounted for nearly USD 1,922 million in 2024 in the 7MM.
CTX-471
- Small Cell Lung Cancer: The global small cell lung cancer therapeutics market size is valued at USD 7.25 billion in 2025 and is predicted to increase to approximately USD 22.86 billion by 2035. Another projection indicates the global market will grow from USD 6.91 billion in 2025 to USD 12.75 billion by 2031. The small cell lung cancer market in the 7MM reached a value of USD 8.9 billion in 2024 and is expected to reach USD 23.0 billion by 2035. The U.S. small cell lung cancer treatment market is estimated to be valued at USD 527.0 million in 2025 and is anticipated to reach USD 1.5 billion by 2035.
- Melanoma: The global melanoma therapeutics market size was valued at USD 4.62 billion in 2024, is predicted to be USD 5.32 billion in 2025, and is expected to be worth USD 17.30 billion by 2033. Other estimates for the global market size include USD 5.83 billion in 2024, reaching USD 10.26 billion by 2030, and USD 7.39 billion in 2025, reaching around USD 17.93 billion by 2034. North America accounted for the largest share of the global melanoma therapeutics market, leading with a 41% market share in 2024. The U.S. melanoma therapeutics market was valued at USD 0.52 billion in 2023 and is expected to reach USD 1.14 billion by 2032.
CTX-8371
- PD-1 and PD-L1 Inhibitors (Oncology): The global PD-1 and PD-L1 inhibitors market size is forecast to increase by USD 49.3 billion at a compound annual growth rate (CAGR) of 18.3% between 2023 and 2028. The market size was valued at USD 49.15 billion in 2024 and is poised to grow to USD 209.83 billion by 2033. Another report estimates the market size at USD 63.73 billion in 2025, expected to reach USD 145.56 billion by 2030. North America currently dominates the global PD-1/PD-L1 inhibitors market, accounting for 43.21% of the revenue in 2025.
AI Analysis | Feedback
Here are 3-5 expected drivers of future revenue growth for Compass Therapeutics (CMPX) over the next 2-3 years:
- Potential Commercialization of Tovecimig (CTX-009) in Biliary Tract Cancer (BTC): Compass Therapeutics' lead investigational bispecific antibody, tovecimig (CTX-009), is in a Phase 2/3 clinical trial for biliary tract cancers. The company anticipated pivotal progression-free survival and overall survival analyses from the COMPANION-002 study in late first quarter 2026. Tovecimig met its primary efficacy endpoint in April 2025, and Compass Therapeutics aims to file with regulators later in 2026. Successful regulatory approval and subsequent launch in this market, estimated to be around $1.4 billion annually in the U.S., would be a significant driver of revenue.
- Expansion of Tovecimig (CTX-009) into Additional Indications: Beyond biliary tract cancer, tovecimig is also being developed for other indications. A Phase 2 study in patients with DLL4-positive colorectal cancer was expected to initiate in mid-2025, with additional Phase 2 monotherapy data in metastatic colorectal cancer showcased at the 2026 ASCO GI Cancers Symposium, demonstrating differentiated activity. Success in expanding the approved indications for tovecimig would broaden its market reach and revenue potential.
- Advancement and Potential Commercialization of CTX-471: CTX-471, a monoclonal antibody, is in Phase I clinical trials for solid tumors. A Phase 2 trial of CTX-471 in patients with tumors expressing NCAM (CD56) is expected to begin in the first quarter of 2026. [cite: BACKGROUND, 20] Promising clinical responses and a correlation between NCAM expression and disease control have been observed in earlier studies, positioning CTX-471 as a potential revenue contributor if clinical development continues positively.
- Progression of CTX-8371 through Clinical Trials: CTX-8371, a bispecific inhibitor targeting PD-1 and PD-L1, is undergoing a Phase 1 clinical trial. Preliminary data was expected in the second half of 2025, and encouraging early clinical signals, including durable responses in triple-negative breast cancer and Hodgkin lymphoma, have led to cohort expansions in these areas. [cite: BACKGROUND, 13, 17, 25] Results from the fifth cohort are anticipated to be presented at a major medical conference in the first half of 2026. Continued positive data and advancement to later-stage trials or accelerated pathways could pave the way for future revenue.
- Initiation of CTX-10726 Clinical Trials: Compass Therapeutics is advancing CTX-10726, a novel PD-1 x VEGF-A bispecific antibody, with an Investigational New Drug (IND) application expected by the end of 2025 and initial proof-of-concept clinical data anticipated in 2026. The company planned to initiate a Phase 1 study of CTX-10726 in the first quarter of 2026. Preclinical data indicating superior tumor control compared to a competitor suggests significant potential for this new product candidate to contribute to future revenue if clinical development is successful.
AI Analysis | Feedback
Capital Allocation Decisions for Compass Therapeutics (CMPX)
Share Issuance
- Compass Therapeutics' shares outstanding have shown consistent growth, increasing from 61.69 million in 2021 to 180.09 million by March 2026.
- In August 2025, Compass Therapeutics priced a $120 million stock offering.
Inbound Investments
- As of the latest reports, 200 institutional owners hold a total of 163,725,703 shares in Compass Therapeutics.
- Significant institutional shareholders include Tang Capital Management Llc, Orbimed Advisors Llc, and BlackRock, Inc.
- BlackRock, Inc. reported a 5.2% passive stake in the company as of January 21, 2026.
Capital Expenditures
- Capital expenditures in the most recent quarter (Q4 2025) totaled -$0.007 million USD.
- For the full fiscal year 2025, capital expenditures were reported as $25,000.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Compass Therapeutics Earnings Notes | 12/16/2025 |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to CMPX.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 04302026 | GEHC | GE HealthCare Technologies | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | IQV | IQVIA | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | UHS | Universal Health Services | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ABT | Abbott Laboratories | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ZBIO | Zenas BioPharma | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 19.46 |
| Mkt Cap | 1.5 |
| Rev LTM | 128 |
| Op Inc LTM | -74 |
| FCF LTM | -44 |
| FCF 3Y Avg | -62 |
| CFO LTM | -43 |
| CFO 3Y Avg | -61 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 2.8% |
| Rev Chg 3Y Avg | 8.6% |
| Rev Chg Q | 5.8% |
| QoQ Delta Rev Chg LTM | 1.3% |
| Op Inc Chg LTM | 10.3% |
| Op Inc Chg 3Y Avg | -8.8% |
| Op Mgn LTM | -48.7% |
| Op Mgn 3Y Avg | -136.3% |
| QoQ Delta Op Mgn LTM | -0.1% |
| CFO/Rev LTM | -31.1% |
| CFO/Rev 3Y Avg | -77.6% |
| FCF/Rev LTM | -33.4% |
| FCF/Rev 3Y Avg | -79.9% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 1.5 |
| P/S | 4.9 |
| P/Op Inc | -3.5 |
| P/EBIT | -3.6 |
| P/E | -3.7 |
| P/CFO | -3.6 |
| Total Yield | -11.3% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | -11.1% |
| D/E | 0.1 |
| Net D/E | -0.2 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -5.0% |
| 3M Rtn | 3.2% |
| 6M Rtn | 7.8% |
| 12M Rtn | 40.6% |
| 3Y Rtn | -26.5% |
| 1M Excs Rtn | -15.4% |
| 3M Excs Rtn | -4.7% |
| 6M Excs Rtn | 4.5% |
| 12M Excs Rtn | 5.7% |
| 3Y Excs Rtn | -102.6% |
Price Behavior
Price Behavior
| Market Price | $1.81 | |
| Market Cap ($ Bil) | 0.3 | |
| First Trading Date | 11/02/2021 | |
| Distance from 52W High | -72.9% | |
| 50 Days | 200 Days | |
| DMA Price | $4.79 | $4.58 |
| DMA Trend | up | down |
| Distance from DMA | -62.2% | -60.5% |
| 3M | 1YR | |
| Volatility | 143.7% | 93.1% |
| Downside Capture | 1.59 | 0.36 |
| Upside Capture | -294.49 | 52.24 |
| Correlation (SPY) | 14.7% | 15.8% |
CMPX Betas & Captures as of 4/30/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 3.30 | 1.44 | 1.44 | 1.26 | 1.25 | 1.50 |
| Up Beta | 5.26 | 4.16 | 3.50 | 2.09 | 1.90 | 1.34 |
| Down Beta | -7.16 | 1.48 | 1.55 | 1.23 | 1.24 | 1.58 |
| Up Capture | -387% | -268% | -182% | -36% | 46% | 175% |
| Bmk +ve Days | 15 | 22 | 31 | 66 | 141 | 428 |
| Stock +ve Days | 13 | 22 | 30 | 64 | 132 | 354 |
| Down Capture | 1447% | 249% | 223% | 134% | 90% | 111% |
| Bmk -ve Days | 4 | 18 | 30 | 56 | 108 | 321 |
| Stock -ve Days | 9 | 20 | 33 | 57 | 107 | 364 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CMPX | |
|---|---|---|---|---|
| CMPX | 6.3% | 93.2% | 0.68 | - |
| Sector ETF (XLV) | 9.7% | 15.4% | 0.40 | 16.2% |
| Equity (SPY) | 29.6% | 12.5% | 1.86 | 16.0% |
| Gold (GLD) | 37.0% | 27.1% | 1.14 | 2.4% |
| Commodities (DBC) | 48.7% | 18.0% | 2.12 | -7.5% |
| Real Estate (VNQ) | 12.9% | 13.5% | 0.65 | 14.9% |
| Bitcoin (BTCUSD) | -16.3% | 42.1% | -0.31 | 10.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CMPX | |
|---|---|---|---|---|
| CMPX | -14.7% | 87.9% | 0.24 | - |
| Sector ETF (XLV) | 5.3% | 14.6% | 0.18 | 18.6% |
| Equity (SPY) | 12.8% | 17.1% | 0.59 | 19.4% |
| Gold (GLD) | 21.1% | 17.9% | 0.96 | 5.8% |
| Commodities (DBC) | 14.1% | 19.1% | 0.60 | 5.1% |
| Real Estate (VNQ) | 3.3% | 18.8% | 0.08 | 18.8% |
| Bitcoin (BTCUSD) | 7.0% | 56.0% | 0.34 | 12.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CMPX | |
|---|---|---|---|---|
| CMPX | -7.7% | 87.9% | 0.24 | - |
| Sector ETF (XLV) | 9.3% | 16.5% | 0.45 | 18.6% |
| Equity (SPY) | 15.0% | 17.9% | 0.72 | 19.4% |
| Gold (GLD) | 13.5% | 16.0% | 0.70 | 5.8% |
| Commodities (DBC) | 9.4% | 17.8% | 0.44 | 5.1% |
| Real Estate (VNQ) | 5.7% | 20.7% | 0.24 | 18.8% |
| Bitcoin (BTCUSD) | 68.2% | 66.9% | 1.07 | 12.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 3/5/2026 | -2.8% | -1.8% | -4.2% |
| 11/5/2025 | 0.8% | 22.2% | 45.9% |
| 8/11/2025 | 23.7% | 10.0% | 28.9% |
| 5/8/2025 | 1.1% | 13.6% | 42.0% |
| 2/27/2025 | -1.7% | -6.7% | -29.3% |
| 11/12/2024 | -5.8% | -28.9% | -12.1% |
| 8/12/2024 | 3.7% | 6.4% | 45.0% |
| 3/21/2024 | 5.7% | -3.3% | -30.7% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 6 | 6 | 5 |
| # Negative | 5 | 5 | 6 |
| Median Positive | 2.6% | 11.2% | 42.0% |
| Median Negative | -2.8% | -6.7% | -11.6% |
| Max Positive | 23.7% | 22.2% | 45.9% |
| Max Negative | -6.4% | -28.9% | -30.7% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/05/2026 | 10-Q |
| 12/31/2025 | 03/05/2026 | 10-K |
| 09/30/2025 | 11/05/2025 | 10-Q |
| 06/30/2025 | 08/11/2025 | 10-Q |
| 03/31/2025 | 05/08/2025 | 10-Q |
| 12/31/2024 | 02/27/2025 | 10-K |
| 09/30/2024 | 11/12/2024 | 10-Q |
| 06/30/2024 | 08/12/2024 | 10-Q |
| 03/31/2024 | 05/13/2024 | 10-Q |
| 12/31/2023 | 03/21/2024 | 10-K |
| 09/30/2023 | 11/09/2023 | 10-Q |
| 06/30/2023 | 08/03/2023 | 10-Q |
| 03/31/2023 | 05/04/2023 | 10-Q |
| 12/31/2022 | 03/15/2023 | 10-K |
| 09/30/2022 | 11/09/2022 | 10-Q |
| 06/30/2022 | 08/01/2022 | 10-Q |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Schuetz, Thomas J | CHIEF EXECUTIVE OFFICER | Direct | Buy | 5272025 | 2.11 | 10,000 | 21,100 | 13,674,541 | Form |
| 2 | Gordon, Carl L | See footnotes | Sell | 4112025 | 1.59 | 3,571,428 | Form | |||
| 3 | Orbimed, Advisors Llc | See footnotes | Sell | 4112025 | 1.59 | 3,571,428 | Form | |||
| 4 | Anderman, Jonathan | Gen Counsel & Corporate Sec | Direct | Buy | 4082025 | 1.54 | 20,000 | 30,800 | 32,340 | Form |
| 5 | Lerner, Neil | CHIEF ACCOUNTING OFFICER | Direct | Buy | 4082025 | 1.42 | 20,000 | 28,400 | 454,400 | Form |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.